Petros Grivas is Clinical Director of the Genitourinary Cancers (GU) Programme and Associate Professor in the Department of Medicine, Division of Oncology, at the University of Washington, in Seattle, WA, USA. He is a board-certified medical oncologist with expertise and experience in treating genitourinary cancers.
Dr Grivas graduated with a degree in medicine from the University of Patras Medical School, Patras, Greece, in 2005, and subsequently earned his PhD in medical oncology in 2008. He completed his residency in internal medicine at Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA, USA, in 2010, before undertaking a fellowship in haematology/oncology at the University of Michigan, Ann Arbor, MI, USA, which he completed in 2013. Dr Grivas served as Clinical Lecturer at the University of Michigan, before being appointed Assistant Professor at the Cleveland Clinic, in Cleveland, OH, USA, where he led the bladder/urothelial cancer programme, undertook clinical and translational research, taught trainees, and treated patients with GU cancers.
Dr Grivas played a central role in clinical trials that led to the US Food and Drug Administration (FDA) approval of new drugs for bladder/urothelial cancer, and is considered a key opinion leader and international expert in his field. Actively involved in oncology education and research, he gives lectures internationally, helping to educate oncologists, other healthcare providers, and trainees; he also leads large innovative clinical trials, reviews grant proposals and manuscripts, and publishes novel and important research. Dr Grivas is dedicated to efficient, personalized, and outstanding patient care and believes in optimal patient–physician relationships as well as community outreach.
EM-10289 - Date of preparation: April 2019